Cargando…
Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372696/ https://www.ncbi.nlm.nih.gov/pubmed/35965815 http://dx.doi.org/10.21037/atm-22-3234 |
| _version_ | 1784767444368228352 |
|---|---|
| author | Tatangelo, Mark |
| author_facet | Tatangelo, Mark |
| author_sort | Tatangelo, Mark |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9372696 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93726962022-08-13 Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications Tatangelo, Mark Ann Transl Med Editorial AME Publishing Company 2022-07 /pmc/articles/PMC9372696/ /pubmed/35965815 http://dx.doi.org/10.21037/atm-22-3234 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Tatangelo, Mark Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title | Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title_full | Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title_fullStr | Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title_full_unstemmed | Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title_short | Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| title_sort | measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372696/ https://www.ncbi.nlm.nih.gov/pubmed/35965815 http://dx.doi.org/10.21037/atm-22-3234 |
| work_keys_str_mv | AT tatangelomark measuringagreyareainmedicationdeploymentrevealsdelaysfrominventiontoclinicaluseofrheumatoidarthritismedications |